Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:public_company
|
| gptkbp:CEO |
gptkb:Paul_J._Diaz
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:CUSIP |
62855J104
|
| gptkbp:foundedYear |
1991
|
| gptkbp:hasCompany |
gptkb:Myriad_Genetics,_Inc.
|
| gptkbp:headquartersLocation |
gptkb:Salt_Lake_City,_Utah,_United_States
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:ISIN |
US62855J1043
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:marketCap |
mid-cap
|
| gptkbp:products |
molecular diagnostics
genetic testing hereditary cancer tests oncology tests |
| gptkbp:stockSymbol |
gptkb:NASDAQ
gptkb:MYGN |
| gptkbp:tradedOn |
gptkb:MYGN
|
| gptkbp:website |
https://www.myriad.com/
|
| gptkbp:bfsParent |
gptkb:Myriad_Genetics
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
NASDAQ: MYGN
|